(firstQuint)Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus in Type 1 Diabetes Mellitus Patients.

 This multi-center, open-label, randomized clinical extension study in patients with T1DM will assess safety and efficacy of Mylan's insulin glargine and Lantus(R).

 Patients with an established diagnosis of T1DM per American Diabetes Association 2014 criteria who were randomized to the Lantus(R) treatment arm of the Mylan Glargine 3001 study, and who have completed the 52-week treatment period on Lantus(R) will be eligible to be screened for the MYL-1501D-3003 study.

.

 Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus in Type 1 Diabetes Mellitus Patients@highlight

The aim of this extension study is to assess the safety and efficacy of Mylan's insulin glargine and Lantus(R) in T1DM patients.

